- Home
- KG vs KZIA Comparison
KG vs KZIA Comparison
Compare KG & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KG | KZIA |
|---|---|---|
| Founded | N/A | 1994 |
| Country | Bermuda | Australia |
| Employees | 44 | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 87.3M | 100.8M |
| IPO Year | N/A | 2002 |
Fundamental Metrics
Financial Performance| Metric | KG | KZIA |
|---|---|---|
| Price | $11.27 | $14.77 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $19.50 |
| AVG Volume (30 Days) | 4.7K | ★ 188.8K |
| Earning Date | 05-15-2026 | 06-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $1.38 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.07 | $4.86 |
| 52 Week High | $31.45 | $17.40 |
Technical Indicators
Market Signals| Indicator | KG | KZIA |
|---|---|---|
| Relative Strength Index (RSI) | 46.23 | 64.05 |
| Support Level | $10.63 | $5.62 |
| Resistance Level | $12.30 | $17.40 |
| Average True Range (ATR) | 0.75 | 1.06 |
| MACD | -0.03 | 0.23 |
| Stochastic Oscillator | 13.57 | 89.70 |
Price Performance
Historical ComparisonAbout KG Kestrel Group Ltd.
Kestrel Group Ltd specializes in providing fronting services to insurance program managers, MGAs, reinsurers, and reinsurance brokers with two reportable segments: Program Services and Legacy Reinsurance. The Group facilitates insurance transactions utilizing its management contracts with four insurance carriers. Its line business includes casualty, workers' compensation, catastrophe-exposed property, and non-catastrophe-exposed property, with diverse risk durations, sizes, and product types.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.